1. Home
  2. GEG vs CALC Comparison

GEG vs CALC Comparison

Compare GEG & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GEG

Great Elm Group Inc.

N/A

Current Price

$1.87

Market Cap

80.9M

Sector

Technology

ML Signal

N/A

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.56

Market Cap

88.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEG
CALC
Founded
1994
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.9M
88.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
GEG
CALC
Price
$1.87
$0.56
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
53.9K
408.0K
Earning Date
05-06-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.76
$0.46
52 Week High
$3.51
$7.20

Technical Indicators

Market Signals
Indicator
GEG
CALC
Relative Strength Index (RSI) 34.63 32.66
Support Level N/A $0.49
Resistance Level $2.19 $0.79
Average True Range (ATR) 0.10 0.08
MACD -0.00 0.04
Stochastic Oscillator 20.42 11.52

Price Performance

Historical Comparison
GEG
CALC

About GEG Great Elm Group Inc.

Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: